Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

Satellite symposia provide opportunities to learn about new and emerging clinical options not addressed in the
scientific program. While not part of the official scientific program, these industry-supported symposia are an
important part of the ASM as they are planned to meet the same standards of evidence, scientific rigor, and fair
balance as scientific sessions.

Planner: Voxmedia
Disclaimer: This Satellite Symposium is presented through a collaboration between Voxmedia, LLC and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Satellite Review Committee. Satellite sessions are not a part of the scientific program as planned and executed by the HFSA Program Committee.

This activity is supported by an independent educational grant from Alnylam Pharmaceuticals, Inc.